Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genetic deletion of Usp22 in KRASG12D-p53-null driven mouse lung cancer [Visium]

ABSTRACT: Ubiquitin-specific peptidase 22 (USP22), a deubiquitinase and component of the “Death-By-Cancer” 11-gene signature, is overexpressed in multiple cancers and linked to recurrence, therapy resistance, and poor prognosis. While its role in tumor immune evasion is emerging, the function of USP22 in KRAS-driven lung cancer and antitumor immunity remains largely unknown. Given that oncogenic KRAS promotes an immunosuppressive tumor microenvironment (TME) and resistance to immunotherapy, this study investigates USP22's role in KRAS-driven lung cancer and its potential impacts on carcinogenesis and anticancer immunity. For this purpose, Usp22 knockout (Usp22-KO) mouse model was developed in the KRASG12D; p53−/− (KP) background, cancers were induced, and spatial transcriptomics was applied to define the difference in TME of mouse KP verse USP22-KO-KP (KPU-) lung cancer.

ORGANISM(S): Mus musculus

PROVIDER: GSE306019 | GEO | 2026/08/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genetic deletion of Usp22 in KRASG12D-p53-null driven lung cancer [RNA-Seq]

Project description:Ubiquitin-specific peptidase 22 (USP22), a deubiquitinase and component of the “Death-By-Cancer” 11-gene signature, is overexpressed in multiple cancers and linked to recurrence, therapy resistance, and poor prognosis. While its role in tumor immune evasion is emerging, the function of USP22 in KRAS-driven lung cancer and antitumor immunity remains largely unknown. Given that oncogenic KRAS promotes an immunosuppressive tumor microenvironment (TME) and resistance to immunotherapy, this study investigates USP22's role in KRAS-driven lung cancer and its potential impacts on carcinogenesis and anticancer immunity. For this purpose, Usp22 knockout (Usp22-KO) mouse model was developed in the KRASG12D; p53−/− (KP) background, cancers were induced, and bulk RNA-seq analysis was applied to indentify differentially expressed genes and alterated signaling pathways in USP22-KO-KP (KPU-) lung cancers, compared to KP lung cancers.

2026-08-20 | GSE306017 | GEO

Transcriptional profiling of Usp22-WT and Usp22-KO pancreatic tumor cells

Project description:RNA-seq analysis of sorted Usp22-WT and Usp22-KO tumor cells from subcutaneously implanted mouse pancreatic tumors

2019-11-08 | GSE140088 | GEO

Transcriptional profiling of Usp22-WT and Usp22-KO pancreatic tumor cells

Project description:Transcriptional profiling of Usp22-WT and Usp22-KO pancreatic tumor cells

| PRJNA588235 | ENA

KRAS and YAP1 converge to regulate EMT and tumor survival

Project description:Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to express an inducible KRAS-specific shRNA. We found 147 genes that promoted survival in the setting of KRAS suppression. In this model, the transcriptional co-activator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. Acquired resistance to Kras suppression in a Kras-driven murine lung cancer model also involved increased YAP1 signaling. KRAS and YAP1 converge on the transcription factor FOS and activate a transcriptional program involved in regulating the epithelial-mesenchymal transition (EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as a significant component of oncogenic RAS signaling Three biological replicates of primary lung adenocarcinoma cells derived from the Kras Lox-STOP-Lox-G12D;p53flox/flox (KP) mouse lung cancer model into which a doxycycline-inducible shRNA targeting Kras expressed from the 3’UTR of GFP was introduced (KP-KrasA cells) were analyzed at timepoints (days) D0, D4, and D21.

2014-07-27 | E-GEOD-56175 | biostudies-arrayexpress

Transcriptomic analysis of lung adenocarcinomas from KP and KPCic mice

Project description:The transcriptional repressor Capicua (CIC) is negatively regulated by KRAS/MAPK signaling. To characterize the impact of CIC loss on KrasG12V/Trp53-KO-driven lung adenocarcinomas in mice, the transcriptome of tumors from Kras (+/LSLG12V); Trp53 (lox/lox) [KP] and Kras (+/LSLG12V); Trp53 (lox/lox); Cic (lox/lox) [KPCic] mice are compared.

2025-09-11 | GSE303269 | GEO

Global transcriptional profiling changes upon knockout of USP22 in human Non-small cell lung cancer cells

Project description:The experiment was designed to display differential gene expression profiling changes in two human non-small cell lung cancer cells A549 and H1299 upon knockout of USP22 gene, by using RNAseq technology.

2019-10-01 | GSE131934 | GEO

USP22 Facilitates Gastric Cancer Progression via Hippo/YAP axis

Project description:Gastric cancer (GC) is one of the most common malignancies in the digestive system. Previous studies demonstrated that the dysregulation of the Hippo pathway and hyperactivation of the YAP/TEAD transcriptional axis played important roles in GC progression, although the underlying mechanisms remain incompletely understood. Our study demonstrated that the deubiquitinase USP22 plays a pivotal role in regulating the Hippo pathway in GC, where its inhibition markedly suppresses YAP/TEAD activity and tumor progression. Mechanistically, USP22 interacts with YAP and inhibits its K48-linked polyubiquitination, thereby enhancing YAP protein stability and Hippo/YAP axis activity in GC. Intriguingly, YAP can transcriptionally upregulate USP22 by binding to its promoter region, establishing a positive feedback loop that promotes gastric cancer progression. Collectively, our findings reveal a reciprocal activation mechanism between USP22 and the Hippo pathway in gastric tumorigenesis, identifying USP22 as a promising novel therapeutic target.

2026-06-01 | GSE319116 | GEO

Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer [CUT&Tag]

Project description:Small cell lung cancer (SCLC) responds exceptionally well to cytotoxic chemotherapy. However, relapse with the emergence of chemoresistant disease is rapid and accompanied by poor treatment outcomes. To understand the genetic basis of chemoresistance in SCLC, we applied in vivo CRISPR deletion screening to patient-derived xenograft (PDX) models. Top screen hits included genes encoding components of the transcriptional co-activator SAGA (Spt-Ada-Gcn5 acetyltransferase) complex. We demonstrate that deletion of the SAGA deubiquitylase USP22 conferred cisplatin/etoposide resistance in two chemosensitive PDX models, and that restoring expression in a PDX model harboring homozygous truncating mutation of USP22 re-sensitized tumors to chemotherapy. USP22 loss increased gene body histone H2A-K119 monoubiquitylation in genes encoding key regulators of neuronal differentiation, and suppressed neural and neuroendocrine gene expression including targets of ASCL1. Chemoresistance following USP22 loss reflected attenuated DNA damage-driven phosphorylation events and apoptosis, in conjunction with increased expression of glycolysis and hypoxia-related genes. Glycolysis program upregulation may reflect a targetable vulnerability, as inhibition of GLUT1 re-sensitized USP22-null tumors to chemotherapy.

2025-05-08 | GSE296258 | GEO

Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer [RNA-seq]

2025-05-08 | GSE296155 | GEO

ACC-MESO1 cells: Control shRNA vs USP22 shRNA

Project description:USP22 plays oncogenic role and in order to study molecular mechanism of USP22 to promote tumorigenesis, microarray analysis was performed on USP22 knockdowned cells.

2018-10-01 | GSE104929 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data